Status:
COMPLETED
Soluble Neprilysin, NT-proBNP, and Growth-Differentiation-Factor-15 as Biomarkers for Heart Failure in Dialysis Patients
Lead Sponsor:
Hannover Medical School
Collaborating Sponsors:
Institut National de la Santé Et de la Recherche Médicale, France
F-CRIN
Conditions:
Heart Failure
End Stage Renal Disease
Eligibility:
All Genders
18+ years
Brief Summary
Objectives: The aim of this study is to determine whether growth differentiation factor-15 (GDF15) and circulating neprilysin (cNEP) improve the diagnosis of congestive heart failure (HF) in patients ...
Eligibility Criteria
Inclusion
- ESRD on either chronic hemodialysis (HD) or peritoneal dialysis (PD) for ≥3 months
Exclusion
- previous switch of the type of renal replacement therapy from HD to PD or vice versa
- age \<18 years
- pregnancy
- plasma exchange or apheresis in the past 6 months
- unipolar pacemaker
- history of whole extremity amputation
Key Trial Info
Start Date :
August 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2019
Estimated Enrollment :
153 Patients enrolled
Trial Details
Trial ID
NCT04061811
Start Date
August 1 2018
End Date
February 28 2019
Last Update
August 20 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Inserm Umr S-942
Paris, France
2
Hannover Medical School
Hanover, Germany, 30175